{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:46:51Z","timestamp":1789663611975,"version":"4.0.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.vaccine.2020.03.003","type":"journal-article","created":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T09:02:58Z","timestamp":1584435778000},"page":"3305-3312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["E. coli production process yields stable dengue 1 virus-sized particles (VSPs)"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3090-9878","authenticated-orcid":false,"given":"Janet","family":"Hirsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart W.","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"James E.","family":"Crowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babs","family":"Verstrepen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesine","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.03.003_b0005","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nm.2105","article-title":"A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection","volume":"16","author":"Akahata","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2020.03.003_b0010","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1128\/JVI.75.9.4268-4275.2001","article-title":"Mutational evidence for an internal fusion peptide in flavivirus envelope protein E","volume":"75","author":"Allison","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.03.003_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bpc.2006.12.007","article-title":"Suppression of protein interactions by arginine: A proposed mechanism of the arginine effects","volume":"127","author":"Arakawa","year":"2007","journal-title":"Biophys Chem"},{"key":"10.1016\/j.vaccine.2020.03.003_b0020","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/pol.1958.1203312618","article-title":"Interaction between particles suspended in solutions of macromolecules","volume":"33","author":"Asakura","year":"1958","journal-title":"J Polym Sci"},{"key":"10.1016\/j.vaccine.2020.03.003_b0025","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1021\/bi047528r","article-title":"Role of arginine in the stabilization of proteins against aggregation","volume":"44","author":"Baynes","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.vaccine.2020.03.003_b0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005608","article-title":"Zika virus-like particle (VLP) based vaccine","volume":"11","author":"Boigard","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2020.03.003_b0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001760","article-title":"Refining the global spatial limits of dengue virus transmission by evidence-based consensus","volume":"6","author":"Brady","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2020.03.003_b0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001176","article-title":"Inhibition of protein aggregation: supramolecular assemblies of arginine hold the key","volume":"2","author":"Das","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.03.003_b0045","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.1073\/pnas.1200566109","article-title":"Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions","volume":"109","author":"de Alwis","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2020.03.003_b0050","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.micron.2010.06.003","article-title":"Negative staining and cryo-negative staining of macromolecules and viruses for TEM","volume":"42","author":"De Carlo","year":"2011","journal-title":"Micron"},{"key":"10.1016\/j.vaccine.2020.03.003_b0055","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ni.3058","article-title":"A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus","volume":"16","author":"Dejnirattisai","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2020.03.003_b0060","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jbiotec.2015.12.018","article-title":"High-throughput process development of an alternative platform for the production of virus-like particles in Escherichia coli","volume":"219","author":"Effio","year":"2016","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2020.03.003_b0070","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S1097-2765(01)00206-4","article-title":"Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus","volume":"7","author":"Ferlenghi","year":"2001","journal-title":"Mol Cell"},{"key":"10.1016\/j.vaccine.2020.03.003_b0075","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1126\/science.aaa8651","article-title":"Dengue Virus. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers","volume":"349","author":"Fibriansah","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.03.003_b0080","doi-asserted-by":"crossref","DOI":"10.1002\/emmm.201303404","article-title":"A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface","author":"Fibriansah","year":"2014","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.vaccine.2020.03.003_b0085","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.4049\/jimmunol.1300504","article-title":"DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza","volume":"191","author":"Grodeland","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.03.003_b0090","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.03.003_b0095","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0065-3527(03)60011-4","article-title":"Neutralization and antibody-dependent enhancement of dengue viruses","volume":"60","author":"Halstead","year":"2003","journal-title":"Adv Virus Res"},{"issue":"23","key":"10.1016\/j.vaccine.2020.03.003_b0105","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1016\/S0264-410X(00)00032-3","article-title":"Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice","volume":"18","author":"Kelly","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.03.003_b0110","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4269\/ajtmh.16-0503","article-title":"Recombinant dengue virus 4 envelope glycoprotein virus-like particles derived from Pichia pastoris are capable of eliciting homotypic domain III-directed neutralizing antibodies","volume":"96","author":"Khetarpal","year":"2017","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2020.03.003_b0115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/14760584.2018.1411198","article-title":"EDiP: the epitope dilution phenomenon. Lessons learnt from a malaria vaccine antigen and its applicability to polymorphic antigens","volume":"17","author":"Kusi","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2020.03.003_b0125","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11262-009-0418-2","article-title":"Recombinant dengue virus-like particles from Pichia pastoris: efficient production and immunological properties","volume":"40","author":"Liu","year":"2010","journal-title":"Virus Genes"},{"key":"10.1016\/j.vaccine.2020.03.003_b0130","doi-asserted-by":"crossref","DOI":"10.1186\/s12866-014-0233-3","article-title":"Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties","volume":"14","author":"Liu","year":"2014","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.vaccine.2020.03.003_b0135","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.copbio.2007.10.013","article-title":"Virus-like particles - universal molecular toolboxes","volume":"18","author":"Ludwig","year":"2007","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.vaccine.2020.03.003_b0140","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(11)60246-8","article-title":"Dengue vector control strategies in an urban setting: an economic modelling assessment","volume":"377","author":"Luz","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.03.003_b0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064595","article-title":"Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without Pre-membrane protein and induces high titer neutralizing antibodies","volume":"8","author":"Mani","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.03.003_b0150","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10529-010-0236-6","article-title":"Exploring different strategies to express Dengue virus envelope protein in a plant system","volume":"32","author":"Mart\u00ednez","year":"2010","journal-title":"Biotechnol Lett"},{"key":"10.1016\/j.vaccine.2020.03.003_b0155","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.virol.2008.11.013","article-title":"Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III","volume":"384","author":"Matsui","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2020.03.003_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002124","article-title":"Effective chikungunya virus-like particle vaccine produced in insect cells","volume":"7","author":"Metz","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2020.03.003_b0165","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1099\/vir.0.000113","article-title":"Physico-chemical requirements and kinetics of membrane fusion of flavivirus-like particles","volume":"96","author":"Modis","year":"2015","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2020.03.003_b0175","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.03.003_b0180","doi-asserted-by":"crossref","DOI":"10.1186\/s12896-016-0280-y","article-title":"Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies","volume":"16","author":"Poddar","year":"2016","journal-title":"BMC Biotechnol"},{"key":"10.1016\/j.vaccine.2020.03.003_b0185","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-26904-5","article-title":"Dengue envelope-based \u2018four-in-one\u2019 virus-like particles produced using Pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice","volume":"8","author":"Rajpoot","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2020.03.003_b0195","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/jctb.673","article-title":"Aqueous two-phase systems for the recovery of a recombinant viral coat protein from Escherichia coli","volume":"77","author":"Rito-Palomares","year":"2002","journal-title":"J Chem Technol Biotechnol"},{"key":"10.1016\/j.vaccine.2020.03.003_b0200","series-title":"Advances in virus research","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0065-3527(03)59005-4","article-title":"Antigenic structure of flavivirus proteins","author":"Roehrig","year":"2003"},{"key":"10.1016\/j.vaccine.2020.03.003_b0205","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/jps.23814","article-title":"Characterization of a laboratory-scale container for freezing protein solutions with detailed evaluation of a freezing process simulation","volume":"103","author":"Roessl","year":"2014","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2020.03.003_b0215","doi-asserted-by":"crossref","first-page":"6242","DOI":"10.1073\/pnas.0508391103","article-title":"Global traffic and disease vector dispersal","volume":"103","author":"Tatem","year":"2006","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2020.03.003_b0220","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2015.01005","article-title":"Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies","volume":"6","author":"Tripathi","year":"2015","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2020.03.003_b0225","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01181-17","article-title":"An envelope-modified tetravalent dengue virus-like-particle vaccine has implications for flavivirus vaccine design","volume":"91","author":"Urakami","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.03.003_b0230","series-title":"Global strategy for dengue prevention and control 2012\u20132020","author":"World Health Organization","year":"2012"},{"key":"10.1016\/j.vaccine.2020.03.003_b0235","unstructured":"World Health Organization, editor. Dengue: guidelines for diagnosis, treatment, prevention, and control, New ed. TDR\u00a0: World Health Organization, Geneva; 2009."},{"key":"10.1016\/j.vaccine.2020.03.003_b0240","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jbiosc.2012.06.012","article-title":"Production of Japanese encephalitis virus-like particles using the baculovirus\u2013insect cell system","volume":"114","author":"Yamaji","year":"2012","journal-title":"J Biosci Bioeng"},{"key":"10.1016\/j.vaccine.2020.03.003_b0245","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1006\/viro.1998.9050","article-title":"Expression of human papillomavirus type 16 L1 protein in Escherichia coli: denaturation, renaturation, and self-assembly of virus-like particlesin vitro","volume":"243","author":"Zhang","year":"1998","journal-title":"Virology"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20303327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20303327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:42:36Z","timestamp":1759401756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20303327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":43,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0264410X20303327"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.03.003","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"E. coli production process yields stable dengue 1 virus-sized particles (VSPs)","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}